Due-process concerns in Purdue exec prosecution; Counterfeit kills superbug patient in China;

> The way the government debarred Purdue Pharma general counsel Howard Udell and two other execs from federal healthcare programs for 12 years "raises serious constitutional due process concerns." Story

> A Beijing hospital used a counterfeit drug to treat the 57-year-old sufferer of a superbug infection, killing him. News

> The Supreme Court of India has banned the production of pharma products in four districts of Andhra Pradesh because of pollution problems. Item

> Danish drugmaker Lundbeck's decision to restrict distribution of pentobarbital marks the first time major global pharma company has taken such direct action to ensure its drugs are used to benefit patients, not assist in state-sponsored execution. Story

> Bosch Packaging Technology has unveiled the GKF 702 capsule filling machine, upgrading the GKF 701. Item

> Between 2005 and mid-2010, 200 of 487 pharma products approved by the FDA involved a contract manufacturer. Report

> BioMarin Pharmaceutical will buy a bulk biologics manufacturing plant in Cork, Ireland, from Pfizer. Story

> Citing differences in strategy and government delays, nonprofit integrated health system UPMC says it will not bid on the federal government's proposed vaccine development and production facilities. UPMC release

> Often overlooked, product degradation can lead to market availability of substandard medicines. Article

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)